109 related articles for article (PubMed ID: 42591)
1. International forum update: depot medroxyprogesterone acetate and endometrial carcinoma.
McDaniel EB; Potts M
Int J Gynaecol Obstet; 1979; 17(3):297-9. PubMed ID: 42591
[TBL] [Abstract][Full Text] [Related]
2. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
Int J Cancer; 1991 Sep; 49(2):186-90. PubMed ID: 1831802
[TBL] [Abstract][Full Text] [Related]
3. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
[TBL] [Abstract][Full Text] [Related]
4. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
Pardthaisong T; Gray RH; McDaniel EB
Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
[TBL] [Abstract][Full Text] [Related]
5. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
Kaunitz AM
J Reprod Med; 1996 May; 41(5 Suppl):419-27. PubMed ID: 8725705
[TBL] [Abstract][Full Text] [Related]
6. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.
Vercellini P; De Giorgi O; Oldani S; Cortesi I; Panazza S; Crosignani PG
Am J Obstet Gynecol; 1996 Aug; 175(2):396-401. PubMed ID: 8765259
[TBL] [Abstract][Full Text] [Related]
7. Vaginal bleeding disturbances associated with the discontinuation of long-acting injectable contraceptives. From the World Health Organization Special Programme for Research, Development, and Research Training in Human Reproduction; Task Force on Long-acting Systemic Agents for the Regulation of Fertility.
Gray RH; Parker RA; Diethelm P
Br J Obstet Gynaecol; 1981 Mar; 88(3):317-21. PubMed ID: 7008825
[TBL] [Abstract][Full Text] [Related]
8. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR
BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502
[TBL] [Abstract][Full Text] [Related]
9. Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
Int J Cancer; 1991 Sep; 49(2):182-5. PubMed ID: 1831801
[TBL] [Abstract][Full Text] [Related]
10. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
Int J Cancer; 1991 Sep; 49(2):191-5. PubMed ID: 1831803
[TBL] [Abstract][Full Text] [Related]
11. Statement on injectable contraception.
International Planned Parenthood Federation IPPF
IPPF Med Bull; 1982 Dec; 16(6):3-4. PubMed ID: 12338511
[TBL] [Abstract][Full Text] [Related]
12. Reply to Dr. Edwin B. McDaniel. Exaggerated claims of depo-provera safety.
Minkin SF
Women Health; 1981; 6(1-2):125-9. PubMed ID: 6223451
[TBL] [Abstract][Full Text] [Related]
13. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
Contraception; 1992 Apr; 45(4):299-312. PubMed ID: 1387601
[TBL] [Abstract][Full Text] [Related]
14. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of Cyclofem and depot medroxyprogesterone acetate (DMPA) effects on endometrial vasculature.
Simbar M; Tehrani FR; Hashemi Z; Zham H; Fraser IS
J Fam Plann Reprod Health Care; 2007 Oct; 33(4):271-6. PubMed ID: 17925114
[TBL] [Abstract][Full Text] [Related]
16. Effects of the injectable contraceptive depot medroxyprogesterone acetate in Thai women with liver fluke infestation: final results.
Grossman RA; Asawasena W; Chalpati S; Taewtong D; Tovanabutra S
Bull World Health Organ; 1979; 57(5):829-37. PubMed ID: 161523
[TBL] [Abstract][Full Text] [Related]
17. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
18. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
19. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.
Jeppsson S; Johansson ED; Ljungberg O; Sjöberg NO
Acta Obstet Gynecol Scand; 1977; 56(1):43-8. PubMed ID: 842303
[TBL] [Abstract][Full Text] [Related]
20. Effects of the injectable contraceptive depot medroxyprogesterone acetate in Thai women with liver fluke infestation: results after six months.
Grossman RA; Assawasena V; Chalpati S; Taewtong D
Bull World Health Organ; 1977; 55(1):67-78. PubMed ID: 302157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
